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ABSTRACT
Introduction: Cerebral venous thrombosis (CVT) is a
rare cerebrovascular condition accounting for <1% of
all stroke cases and mainly affects young adults. Its
genetic aetiology is not clearly elucidated.
Methods and analysis: To better understand the
genetic basis of CVT, we have established an
international biobank of CVT cases, Biorepository to
Establish the Aetiology of Sinovenous Thrombosis
(BEAST) which aims to recruit highly phenotyped
cases initially of European descent and later from
other populations. To date we have recruited 745 CVT
cases from 12 research centres. As an initial step, the
consortium plans to undertake a genome-wide
association analysis of CVT using the Illumina
Infinium HumanCoreExome BeadChip to assess the
association and impact of common and low-frequency
genetic variants on CVT risk by using a case–control
study design. Replication will be performed to
confirm putative findings. Furthermore, we aim to
identify interactions of genetic variants with several
environmental and comorbidity factors which will
likely contribute to improve the understanding of the
biological mechanisms underlying this complex
disease.
Ethics and dissemination: BEAST meets all ethical
standards set by local institutional review boards for
each of the participating sites. The research outcomes
will be published in international peer-reviewed open-
access journals with high impact and visibility. The
results will be presented at national and international
meetings to highlight the contributions into improving
the understanding of the mechanisms underlying this
uncommon but important disease. This international
DNA repository will become an important resource for
investigators in the field of haematological and
vascular disorders.
BACKGROUND
Cerebral venous thrombosis (CVT) is a rare
cerebrovascular condition that accounts for
<1% of all strokes,1 with an overall annual
incidence estimated at 1.32 per 100 000
person-years.2 CVT commonly affects young
Strengths and limitations of this study
▪ This study is the largest collaboration on cerebral
venous thrombosis (CVT) conducted to-date and
has the advantage that it includes highly pheno-
typed individuals.
▪ This is the first study that aims to perform a
genome-wide association analysis to assess the
association and impact of common and low-
frequency genetic variants on CVT risk.
▪ Identifying genetic variants associated with CVT
risk will likely contribute to improving our under-
standing of the biological mechanisms under-
lying this disease and may lead to the discovery
of novel therapeutic targets.
▪ A potential limitation of the study is the difficulty
of recruiting a large number of cases due to the
very low incidence and prevalence of this condi-
tion. Major efforts are being made to include as
many research centres able to investigate this
disease across Europe and beyond.
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adults and is more prevalent in women, accounting for
∼75% of the adult affected patients.3 It can lead to
mortality or severe morbidity but generally has a good
clinical outcome particularly following early identiﬁca-
tion of less severe cases using advanced imaging.4
The condition has two broadly different aetiological
mechanisms: thrombosis of cerebral veins with local effects
caused by venous obstruction and thrombosis of the dural
sinuses which may cause intracranial hypertension.
However, both processes usually occur simultaneously
in most patients with thrombosis often present in more
than one sinus.1 5 6 Compared with arterial thrombosis,
CVT is less frequent in terms of incidence and more
variable in its clinical presentation and neuroimaging.7
The condition has multiple risk factors (box 1) and
presents as a diagnostic and therapeutic challenge given
the diversity of symptomatic presentation and variety of
putative aetiological factors.
CVT is a rare manifestation of venous thromboembol-
ism (VTE). Compared with CVT, traditional venous
thrombosis manifestations such as deep vein thrombosis
(DVT) and pulmonary embolism (PE) are much more
common and are diseases of ageing.8
There is a lack of data evaluating the risk of CVT
recurrence, as well as whether the risk factors for CVT
are similar to those for DVT and PE. One recent study
has found that after a 10-year follow-up on patients with
DVT and PE only 5.2% developed CVT,9 while for
patients with CVT only 5.8% developed DVT/PE later
on.10 Therefore, no signiﬁcant link between CVT and
DVT/PE has been found so far.
Interestingly, one study has found no differences in
thrombophilia markers between CVT and patients with
DVT/PE; however, the frequency of other risk factors,
such as oral contraceptive (OC) use, pregnancy or puer-
perium was signiﬁcantly different.11 CVT showed to be
more frequent in women, secondary to hormonal
factors and less often secondary to trauma, immobilisa-
tion or surgery compared with patients with DVT/PE.11
Therefore, it is not clear why CVT occurs less often
than DVT/PE, and age-dependent differences in the
risk proﬁle between CVT and DVT/PE, as well as
genetic factors may play a role in the pathogenesis.
Thus, due to its rarity and risk proﬁle, CVT represents a
particular form of VTE.
Neither the genetic component of CVT nor its herit-
ability has been widely assessed mainly because of its low
incidence and lack of large number of cases. However,
there is reasonable evidence to support a genetic predis-
position to CVT.
A signiﬁcant proportion of cases (∼13–25%) have no
risk factors identiﬁed1 7 suggesting that undetermined
genetic factors may at least partly account for this unex-
plained risk. Although it is a more rare condition, it
does not usually cluster in families and there is no evi-
dence to suggest a Mendelian inheritance.
The genetic component of CVT has so far been
assessed mainly by candidate gene studies. As CVT is
Box 1 Risk factors associated with cerebral venous
thrombosis.3 7
Genetic prothrombotic conditions
▸ Antithrombin deficiency
▸ Protein C and S deficiency
▸ Factor V Leiden mutation
▸ Prothrombin G20120A mutation
▸ Hyperhomocysteinaemia caused by MTHFR C677 T polymorphism
Acquired prothrombotic states
▸ Nephrotic syndrome
▸ Antiphospholipid antibodies
▸ Pregnancy
▸ Puerperium
Systemic inflammatory disease
▸ Systemic lupus erythematosus
▸ Inflammatory bowel disease
▸ Wegener’s granulomatosis
▸ Behcet’s syndrome
▸ Sarcoidosis
▸ Thyroid disease
Systemic infectious disease
▸ Bacterial: septicaemia, endocarditis, typhoid, tuberculosis
▸ Viral: measles, hepatitis, encephalitis, herpes, HIV, cytomegalovirus
▸ Parasitic: malaria, trichinosis
▸ Fungal: aspergillosis
Head and neck infections
▸ Extradural: mastoiditis, sinusitis, otitis, facial cellulitis, osteo-
myelitis, tonsillitis
▸ Intradural/parenchymal: abscess, empyema, meningitis
Haematological disorders
▸ Polycythaemia (primary and secondary)
▸ Thrombocythaemia
▸ Anaemia (including paroxysmal nocturnal haemoglobinuria)
▸ Sickle cell disease
Drugs
▸ Oral contraceptives
▸ L-asparaginase therapy
▸ Hormone supplement therapy
Systemic malignancies
▸ Visceral carcinomas
▸ Lymphomas
▸ Leukaemia
▸ Myeloproliferative disease
Central nervous system tumours
▸ Meningioma, metastases, carcinomatous infiltration
Gastrointestinal disease
▸ Ulcerative colitis, Crohn’s disease
Cardiac disease
▸ Congenital heart disease, cardiac insufficiency
Mechanical causes and trauma
▸ Head injury, injury to sinuses or jugular vein, neurosurgical
procedures, jugular vein catheterisation, lumbar puncture
Others
▸ Cerebral infarcts and haemorrhage
▸ Arteriovenous malformations
▸ Dural arteriovenous malformation
▸ Arachnoid cyst
▸ Internal jugular compression
▸ Severe exfoliative dermatitis
▸ Severe dehydration of any cause
Idiopathic
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known to be associated with inherited thrombophilia,1
most candidate gene studies have assessed mutations
associated with this condition such as factor V Leiden
and prothrombin G20120A mutation.12 Other mutations
investigated by candidate gene studies have included the
MTHFR C677T polymorphism (risk factor for hyperho-
mocysteinaemia),13 the plasminogen activator inhibitor-1
4G/5G polymorphism (risk factor for thrombosis),14
protein Z G79A polymorphism (involved in formation of
blood clots)15 and Janus Kinase-2 V617F mutation
(involved in making haematopoietic cells more sensitive
to growth factors).16 However, the results from such indi-
vidual candidate gene studies have been conﬂicting
mainly because of lack of sufﬁcient power due to the low
number of cases. One large meta-analysis on 1183 CVT
cases and 5189 controls that pooled together results
from 26 candidate gene studies highlighted signiﬁcant
associations of factor V Leiden G1691A mutation
(OR=2.40; 95% CI 1.75 to 3.30; p<10−5) and prothrom-
bin G20120A mutation (OR=5.48; 95% CI 3.88 to 7.74;
p<10−5) in adult populations.17 Interestingly, this study
also found that genes involved in the clotting cascade
provide a greater level of thrombosis risk in the cerebral
venous circulation compared with its arterial circulation
implying a larger genetic liability for CVT compared
with sporadic ischaemic stroke (IS).17 Moreover, previous
studies suggested a stronger genetic component in
younger patients who had stroke compared with older
case of stroke providing additional evidence to support a
strong genetic susceptibility to CVT.18–20
Other thrombophilic factors involved in the coagula-
tion pathway that are associated with an increased risk of
CVT are: protein C, protein S and antithrombin deﬁ-
ciencies.21 These prothrombotic factors are also asso-
ciated with an increased risk of DVT and PE22 23
suggesting that all these venous thrombosis conditions
may have a common genetic component.
An important characteristic of the disease is the
higher prevalence in women. Large epidemiological
studies have conﬁrmed that OC users, particularly users
of third-generation OCs, are at increased risk of VTE.24–26
Although contraceptive drugs are an important factor in
explaining this gender distribution, genetic factors inter-
acting with pharmacological or environmental determi-
nants may also play a signiﬁcant role. In addition, very
little is known about why the rate of CVT is relatively low
given widespread environmental exposures on a popula-
tion level (eg, OCs, sinus infections, etc), suggesting that
an underlying background genetic risk may contribute
to increasing the incidence of CVT in those with
common exposures.
To better understand the genetic basis of CVT, we
have established an international biorepository of highly
characterised CVT cases, Biorepository to Establish the
Aetiology of Sinovenous Thrombosis (BEAST). The
BEAST Consortium includes CVT cases recruited cur-
rently from 10 centres across seven countries in Europe,
and one each from the USA and Mexico.
Our study aims ﬁrst to assess the association and impact
of common and low-frequency genetic variants on CVT
risk by using a case–control study design and second, to
identify interactions of genetic variants with several envir-
onmental and comorbidity factors which collectively will
likely contribute to a better understanding of the bio-
logical mechanisms underlying this complex disease.
METHODS
Study participants
Cases
The ongoing international BEAST Consortium has to-date
recruited DNA and clinical data from 745 patients with
CVT (aged ≥18 years) from 12 research centres located in
the following countries: Belgium, Finland, Greece, Italy,
the Netherlands, Portugal, UK, USA and Mexico.
In all cases, CVT is conﬁrmed by CT or MRI of the
brain and dedicated venography (CT angiography, MR
angiography, or conventional angiogram). The inclusion
criteria for cases are presented in table 1. Detailed pheno-
typic data is provided by each participating centre (box 2).
Owing to differences in the genetic structure between
the different populations participating in the study,27
cases will be split for genetic association analysis into
four groups: West European, South European (Italian
and Portuguese), Finnish and Mexican cases, to obtain
homogeneous populations. The US population is all
European origin (non-Hispanic white). The results will
be presented per ancestral population and then sub-
jected to a pooled meta-analysis of all populations.
Controls
The inclusion criteria for the control population are pre-
sented in table 1.
For the West European CVT cohort, the BEAST study
will use data from previously genotyped control samples,
namely 2469 British controls from the 1958 British Birth
Cohort part of the Wellcome Trust Case Control
Consortium (WTCCC).28 29
In addition, we have recruited healthy age-matched
and sex-matched controls numbering 300 Italians for
Table 1 Inclusion criteria for CVT cases and controls
Inclusion criteria for CVT
cases
Inclusion criteria for
controls
Age ≥18 years at the time of
enrolment
Age ≥18 years at the
time of enrolment
CVT determined using:
▸ CT or MRI brain
▸ Dedicated venography (CTA,
MRA, or conventional
angiogram)
No history of CVT/
stroke or any other
thrombotic or chronic
condition
Patient or relative provision of
informed written consent
Provision of informed
written consent
CTA, CT angiography; CVT, cerebral venous thrombosis; MRA,
MR angiography.
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the South European cohort, 230 Finnish for the Finnish
cohort and 100 Mexicans for the Mexican cohort.
Ethical considerations
BEAST meets all ethical standards set by local institu-
tional review boards for each of the participating sites.
Written informed consent is obtained for all patients
with CVT and controls at each participating research
centre. Patient conﬁdentiality is protected and patient
details are encrypted.
Biological samples
Peripheral blood samples from all participants are
collected in EDTA-coated phials or sodium citrate vacu-
tainers using venipuncture. Genomic DNA is extracted
from peripheral blood using commercially available
DNA isolation kits and stored at −80°C.
Genotyping
Cases
DNA samples for all CVT cases will be processed on the
HumanCoreExome BeadChip v1.0 (Illumina, San Diego,
California, USA) using standard protocols at the Genetic
and Molecular Epidemiology Laboratory, McMaster
University, Canada.
The Illumina Inﬁnium HumanCoreExome BeadChip
contains ∼240 000 exome focused markers, as well as
∼240 000 common tagSNP markers. The functional
exonic markers include non-synonymous variants, stop
altering variants, splice coding variants and variants
located in promoter regions.
Controls
The WTCCC British control sample was genotyped
using the HumanExome BeadChip v1.0 (Illumina, San
Diego, California, USA). The Illumina HumanExome
Beadchip includes 247 870 markers focused on
protein-altering variants selected from >12 000 exome
and genome sequences representing multiple ethnicities
and complex traits.
The Finnish controls have already been genotyped
using the Illumina Inﬁnium HumanCoreExome
BeadChip, while other control samples (Italian and
Mexican) will be genotyped with the same array.
Data analysis
We will perform case–control analysis using logistic
regression assuming an additive genetic model to assess
the association of the genotyped markers with CVT risk.
Rigorous quality control procedures will be applied
according to the recommended exome chip processing
protocol.30
Population stratiﬁcation analysis and testing for
relatedness will be conducted, and outliers will be
removed from analysis. To investigate residual popula-
tion stratiﬁcation, genomic inﬂation factors will be calcu-
lated. Quantile-Quantile plots will be constructed to
assess the quality of the association results. Meta-analysis
of the association results for the participating cohorts
will be performed using a ﬁxed effect model and inverse
variance method of weighted β coefﬁcients and SEs
from each study. Furthermore, the putative positive ﬁnd-
ings will be conﬁrmed by replication in independent
samples to exclude spurious associations. We are cur-
rently collaborating with additional centres to recruit a
replication sample.
We will conduct a reciprocal look up in genome-wide
association studies (GWAS) of other venous thrombosis
conditions (DVT/PE) and potentially pooling of ana-
lyses from these studies if available.
We will undertake a subgroup analysis of CVT cases
with and without history of other venous thrombosis
conditions (DVT/PE). We will also undertake a sub-
group analysis of CVT cases with and without inherited
thrombophilia.
We will assess the interactions of signiﬁcant poly-
morphisms with environmental and comorbidity risk
factors, severity of clinical presentation and outcome.
The power for gene-environment interactions
depends on the magnitude of the environmental expos-
ure frequency. Therefore, the power is higher if the
exposure frequency is low and is lower if the exposure is
high.31
Box 2 Phenotypic data provided by each participating
centre
Demographic data (age, sex, ethnicity).
Date of cerebral venous thrombosis diagnosis.
Clinical presentation and symptoms.
Neuroimaging information including sinus/vein involved and
extent of oedema, haemorrhage.
Family history of thrombotic or cerebrovascular event.
Thrombophilia screening information:
▸ Protein C and S deficiencies,
▸ Genetic polymorphisms (factor V G1691A mutation, prothrom-
bin G20210A mutation),
▸ Antiphospholipid antibodies,
▸ Lupus anticoagulant,
▸ Hyperhomocysteinaemia.
Risk factors and associated conditions:
▸ Other venous thrombosis,
▸ Transient risk factors,
▸ Pregnancy,
▸ Puerperium,
▸ Systemic or brain infections,
▸ Systemic inflammatory disease,
▸ Haematological disorders,
▸ Drugs (oral contraceptives, L-asparaginase therapy, hormone
replacement therapy),
▸ Malignancies,
▸ Bowel disease,
▸ Cardiac disease,
▸ Mechanical causes and trauma (head injury, surgery, etc),
▸ Severe dehydration of any cause.
Modified Rankin scale at last follow-up.
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We will perform sex stratiﬁed analysis, adjusting for
age, and conduct several comparisons (eg, between OC
users and female non-users, cases with factor V Leiden
mutation and cases without the mutation), to highlight
the inﬂuence of genetic factors between different
patient groups. We will also stratify the data by IS status
(cases with IS vs cases without IS).
Sample size and power
Power calculations were performed using the genetic
power calculator CaTS.32 With the current BEAST
repository of 745 CVT cases and a total of ∼3000 con-
trols, the study has 80% power to detect a relative risk of
1.6 at a signiﬁcant p value <10−7 with a population allele
frequency of 30%. However, the likely genetic liability of
this condition17 suggests that this power calculation may
be conservative.
DISCUSSION
The BEAST Consortium is the largest DNA repository of
highly characterised CVT cases established to-date. The
study aims to improve our understanding of the genetics
of CVT by ﬁrst investigating the inﬂuence of common and
low-frequency genetic variants on CVT risk and, second, by
identifying interactions of genetic variants with environ-
mental and comorbidity risk factors. Comprehensive inves-
tigation into the genetics of CVT holds the potential to
allow at-risk groups to be identiﬁed, as well as disease
severity and prognosis to be determined.
In the past several years, the genome-wide association
(GWA) approach facilitated by technological develop-
ments of high-density genome-wide genotyping arrays
has been applied for many complex diseases and has
been successful in identifying thousands of novel
common genetic variants associated with disease risk.33
However, for IS GWA has not been as successful with few
genetic variants identiﬁed34–39 likely due to the paucity
of power in detecting common genetic variants with
small effects which require very large cohorts.40 Another
likely reason for the limited positive results is the clinical
heterogeneity of IS which is known to be inﬂuenced by
a heterogeneous collection of disease pathways.
Considering that CVT is a rare form of stroke affecting a
much younger population and a more clinically homo-
genous form of stroke, we hypothesise that it is likely to
be inﬂuenced by rare genetic variants with potentially
larger effects compared with sporadic stroke.
The use of the Illumina Inﬁnium HumanCoreExome
BeadChip, which includes a signiﬁcant number of
exonic markers, will increase the probability of identify-
ing functional genetic markers with potential large
effects. The exome contains a large amount of rare
protein-altering variants (missense, nonsense single-base
substitutions, insertion–deletions) that are predicted to
have functional roles and/or to be deleterious41 42
which probably account for a considerable amount of
the disease-causing mutations.43 Thus, although the
initial sample size of our CVT cohort is small due to the
low prevalence/incidence of this disease, this highly
phenotyped clinical and DNA repository of CVT cases
has the potential of identifying novel coding functional
variants associated with CVT with potential large effects.
Increasing the sample size with more CVT cases and
replicating any initial ﬁndings is clearly necessary and is
being directly addressed by the BEAST Consortium.
Currently, the main limitation of our study is the insuf-
ﬁcient power to detect genetic variants with small effects
using the genome-wide approach due to the sample size
of our study but continuous efforts are being made to
enhance enrolment. An important advantage of our
study is the thorough phenotyping using stringent inclu-
sion and exclusion criteria and collection of large
amount of clinical variables enabling not just genetic
analysis but also allowing differences of associated risk
factors or outcomes to be evaluated.
Establishing a large DNA repository of CVT cases
worldwide will help elucidate its genetics leading to an
improvement in our understanding of the pathophysio-
logical mechanisms underlying this disease, identifying
groups at risk and potentially facilitating the identiﬁca-
tion of novel therapeutic targets.
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